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ABSTRACT
The small GTPase Rapl regulates cell adhesion, cell survival, gene transcription
and invasion. We have found that Rapl activity can be stimulated by the bioactive lipid
lysophosphatidic acid (LPA) in human breast cancer cells, but not in non-malignant
mammary epithelial cells. The G protein-coupled LPA] receptor has been implicated in
breast cancer metastasis although the molecular mechanisms underlying this process are
largely unknown. We show that Rapl expression is higher in breast cancer cell lines and
tissue. Gene knockdown of Rapl expression significantly impaired LPA-stimulated
migration and invasion of breast cancer cells. We found that Rapl interacts with the
multi-functional scaffolding proteins P-arrestin2 and IQGAP1 that are critical regulators
breast cancer cell invasiveness. Additionally, P-arrestin2 and IQGAP1 associate in
response to LPA and IQGAP1 knockdown blocks breast cancer invasion. Thus, our data
suggests a novel mechanism by which LPA regulates breast cancer cell invasiveness via
Rapl, P-arrestin2, and IQGAP1.

Keywords Breast cancer, invasion, cell motility, cytoskeleton, Rapl, LPA, p-arrestin,
IQGAP1
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Introduction
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1.1. Breast cancer metastasis
Breast cancer is the most common cancer among Canadian women with 1 in 9
women expected to develop the disease during her lifetime and

1

in 28 to die from it

(Canadian Cancer Society, 2009). The metastasis of breast cancer to distant sites, and not
the primary tumor itself, is responsible for the majority of breast cancer-related deaths
[1], Therefore, gaining a better understanding of the molecular mechanisms underlying
the metastatic process is critical in the discovery of new prognostic markers and
improved treatment options for breast cancer patients.
Cancer metastasis, the process by which malignant cells spread from the primary
site and form new tumours, presents a serious clinical problem due to the fact that the
cancer is usually detected after metastasis has occurred. This greatly limits treatment
options and chances of survival for patients [2], The metastasis of cancer cells consists of
several steps including escape from the primary site into the circulatory or lymphatic
system, exit of cells from the circulation and arrest in a new organ (illustrated in Figure
1.1) [2-9]. During this process, the invasiveness and motility of cancer cells are critical
for the exit of the cancer from the primary tumor and arrest in the target organ. At the
cellular level, several processes facilitate the motility and invasion of cancer cells from
the primary tumor site including reorganization of the actin cytoskeleton, focal adhesion
formation and a transition from an epithelial to mesenchymal morphology [10]. The
initial stages of cell motility are characterized by the formation of broad cell membrane
protrusions (lamellipodia) in the direction of extracellular stimuli and attachment of thin
actin-containing membrane projections (filopodia) to the extracellular matrix at sites of
focal adhesions. These events are followed by contraction of the intracellular filamentous
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Steeg, P. 2003. Nature Reviews Cancer. 3: 55-63

Figure 1.1 A schematic representation of the metastatic cascade
Cancer cells surrounded by an intact basement membrane (a) undergo changes in cell-cell
and cell-extracellular-matrix attachment, ability to degrade the surrounding matrix and
motility (b) allowing them to enter the circulation either via the lymphatic system (c) or
directly via the blood circulatory system (d). Cells arrest and extravásate from the
circulatory system at secondary sites (e) followed by formation of micrometastases (f)
which may develop into progressively growing, angiogenic macrometases.
Figure reproduced with permission (Appendix 1).
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actin, which is a major component of the cytoskeleton, and the disassembly of the focal
adhesion at the rear of the cell to ultimately allow the cell to be dragged forward in a
directional manner (depicted in Figure 1.2) [10].
The processes of cytoskeletal reorganization and cell movement are regulated by
several intracellular signaling pathways that are yet to be fully elucidated. In addition to
the capacity to migrate, tumor cells must acquire the ability to invade through
surrounding tissues and vessels in order for metastasis to take place. Proteases such as
matrix metalloproteinases are recruited to the leading edge of the cell where they degrade
and remodel the extracellular matrix [8 ].
Gaining a better understanding of the molecular pathways involved in cancer cell
migration and invasion is expected to be vital in the identification of novel targets for the
design of new therapeutics for cancer patients. This study examines the mechanisms by
which the bioactive lipid molecule lysophosphatidic acid regulates the migration and
invasion of breast cancer cells, via its downstream effect on the small GTPase Rapl and
the scaffolding proteins P-arrestin and IQGAP1.

1.2. Lysophosphatidic acid
1.2.1. Lysophosphatidic acid structure and production
Lysophosphatidic acid (LPA, 1- or 2-acyl-sn-glycerol 3-phosphate) is the simplest
phospholipid found in nature with a structure consisting of a single fatty acyl chain, a
glycerol backbone and a free phosphate group (Figure 1.3) [11, 12], Despite its
simplicity, several structurally different forms of LPA exist in a variety of organisms,
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1) Protrusion of the Leading Edge

2) Adhesion at the Leading Edge

cortex under tension

movement of unpolymenzed actm

Deadhesion at the Trailing Edge

3) Movement of the Cell Body

Adapted from Ananthakrishnan R. and Ehricher A. 2007. International Journal of
Biological Sciences, 3: 303-17
Figure 1.2 A schematic depiction of the different stages of cell movement
The underlying molecular events during cell movement are (1) protrusion of the cell due
to actin polymerization at the leading edge which form lamellopodia, ( 2 ) adhesion of the
cell at focal adhesion sites on the extracellular matrix and deadhesion at the trailing edge
and finally (3) movement of the cell body forward by contractile forces generated at the
cell body and the rear of the cell.
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Phosphatidic
acid (PA)

Lysophosphatidic Lysophosphatidylcholine
acid (LPA)
(LPC)

Adapted from Mills GB & Moolenar WH. 2003. Nature Reviews Cancer. 3: 582-591

Figure 1.3 The production of LPA by the enzymatic actions of phospholipase Ai/A2
and lysophospholipase D (autotaxin)
LPA can be produced by (a) the hydrolysis of phosphatidic acid (PA) via the actions of
phospholipase A i/A2 or soluble phospholipase A2 which cleave the fatty acyl chain or (b)
the hydrolysis of lysophosphatidylcholine (LPC) by LysoPLD (ATX) which catalyze the
removal of the hydrophilic choline headgroup
Figure reproduced with permission (Appendix 1)
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including plants and vertebrates. Of the various LPA species, oleoyl-LPA (1-acyl 18:1
LPA) and palmitoyl-LPA (16:0 LPA) are the most efficacious at eliciting biological
responses such as intracellular calcium mobilization and are widely utilized in studies
[13]. In humans, the concentration of LPA circulating in the plasma is in the low
nanomolar range (-100 nM). However, LPA concentrations at sites of injury can reach
up to 25 pM [14, 15] and ascites from ovarian cancer patients can contain up to 80 pM of
LPA [16-18]. Activated platelets were initially thought to be responsible for the majority
of the LPA found in blood [15]. However, studies have since shown that LPA can also be
produced by the enzymatic actions of phospholipase Ai and A2 (PLAi and PLA2) and
lysophospholipase D (lysoPLD) acting on phosphatidic acid or lysophosphatidylcholine
(Figure 1.2). Other cell types such as fibroblasts, adipocytes, osteoblasts and some cancer
cells have also been implicated in the production of LPA [19, 20],

1.2.2. Physiological and pathophysiological roles of LPA
While early reports identified LPA as an intermediate in intracellular lipid
metabolism, more recent studies have shown that LPA can regulate a diverse array of
cellular responses such as cell survival, growth, proliferation, migration, neurite
retraction, platelet aggregation, smooth muscle contraction and cytokine and chemokine
secretion [18, 21], LPA signaling is implicated in several biological processes including
tissue remodelling, wound healing, neurogenesis, myelination, olfaction, immune and
reproductive function [12, 22-24], To exert its effects during wound healing, LPA
stimulates mesenchymal and epithelial cell proliferation and migration, enhances the
production of matrix metalloproteases and promotes vasoconstriction [12]. Indeed, the
topical application of LPA enhances wound healing in skin [25]. In addition, LPA plays a
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role in several pathophysiological processes such as atherosclerosis and cardiovascular
disease [26, 27],
LPA also regulates the initiation and progression of cancer. High levels of LPA (up to
80 pM) are observed in ascites from ovarian cancer patients [16-18], Furthermore, LPA
can promote ovarian cancer cell proliferation, survival and growth, gene expression and
cell migration [28-30]. Elevated amounts of LPA have also been seen in body fluids from
patients with myeloma, peritoneal, endometrial and cervical cancer [18, 31]. An autocrine
loop exists in prostate cancer where the prostate cancer cells produce high levels of LPA
and subsequently respond to the LPA generated by stimulating the activity of
downstream signaling molecules such as extracellular signal-regulated kinase and
phospholipase D [32], Most notably, autotaxin, a factor previously known to promote
tumor invasion, angiogenesis and metastasis, was discovered to be identical to the LPAproducing enzyme, lysoPLD [33], Increased levels of autotaxin expression are observed
in a number of cancers including glioblastoma, prostate and breast cancer [34],
Furthermore, ectopic expression of autotaxin in MCF-7 breast cancer cells results in
increased motility and invasiveness, relative to vector-transfected control cells [35],
These findings indicated that autotaxin acts to promote tumor growth and motility via the
production of LPA.

1.2.3. Lysophosphatidic acid receptors
LPA signals via its specific G protein-coupled receptors (GPCRs) to elicit its effects
on the cell. The GPCR family of receptors is the largest family of cell-surface receptors,
with approximately 800 different members in humans [36]. More than 60% of the
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pharmaceuticals on the market utilize GPCRs as targets [37]. The structure of GPCRs
constitutes seven transmembrane-spanning a-helical domains, three extracellular loops,
three intracellular loops, an extracellular amino terminus and intracellular carboxy
terminus (Figure 1.4) [38], At least six GPCRs have been identified as receptors for LPA
and are denoted LPAi.6 (summarized in Table 1.1) [39, 40], Two additional GPCRs,
GPR87 and P2Y10, have recently been identified to bind to and respond to LPA [40, 41].
However, further characterization is required to classify these receptors as bona fide LPA
receptors. Although, the studies presented in this thesis will focus on LPAj, the rest of the
LPA receptors will be described briefly.
Of the known LPA receptors, LPAi, LPA2, and LPA3 are specific for LPA and belong
to the endothelial differentiation gene (EDG) family of GPCRs, and are thus designated
as EDG2, EDG4 and EDG7 respectively. LPA1.3 share approximately 50% amino acid
sequence homology with their C-terminal tail being the most divergent [42, 43]. The
remaining LPA receptors are structurally divergent from the EDG family of receptors and
are more related to the purinergic (P2Y) GPCR family. LPA4 (P2Y9) and LPA5 (GPR92)
share about 35% sequence homology [44], LPA6 (P2Y5) is structurally related to LPA4
and possesses a relatively low affinity for LPA compared to LPA 1.5 [40], The putative
LPA receptor GPR87 shows 27% and 25% sequence homology with LPA4 and LPA5
receptors respectively [45], The last GPCR that is believed to be an LPA receptor,
P2Y10, shares 56%, 52%, and 45% sequence homology with LPA4, LPA5, and GPR87,
respectively [41].
LPA1.3 receptors are ubiquitously expressed with high levels of LPA] seen in
human brain, heart, placenta, small intestine, and colon [46]. LPA2 is most abundantly
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Extracellular Region

Amino terminus

Intracellular Region
Ser-rich
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Murph MM, Nguyen GH, Radhakrishna H, and Mills GB. 2008.
Biochimica et Bìophysica - Molecular and Cell Biology o f Lipids. 1781: 547-557

Figure 1.4 A diagrammatic representation of the LPAi receptor in the plasma
membrane
LPAi is a G protein-coupled receptor that is composed of seven transmembrane-spanning
a-helical domains, three extracellular loops (ECL1, ECL2, ECL3), three intracellular
loops (ICL1, ICL2, ICL3), an extracellular amino terminus and an intracellular Cterminal tail
Figure reproduced with permission (Appendix 1)
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Table 1.1 LPA receptor-mediated signaling
Receptor

LPA,

lpa 2

Cellular responses

Physiological/
Pathophysiological
functions

Proliferation, survival,
stress fiber formation,
neurite retraction and
rounding

Brain development,
Neuropathic pain,
Pulmonary fibrosis,
Renal fibrosis

Cell rounding

Vascular injury
(LPAj.2)

G i/ o , G q / n

Neurite elongation

Embryo
implantation and
spacing,
Spermatogenesis,
male mating
activity (LPA1.3)

Neurite retraction, cell
rounding, cell
aggregation

N/D

Stress fiber formation,
neurite retraction, cell
rounding

N/D

G protein
' coupling

Synonyms

VZG-1, EDG2,
Reel.3,
GPR26,
GPCR26

G ¡/o, G q / n ,
G 12/13

G i/ o , G q / 1 1 ,

EDG4

G 12/13

lpa 3

EDG7

LPA4

GPR23, P2Y9,
P2Y5-like

G i/ o , G q / n ,

GPR92,
GPR93

G q /11,

GPR95

N/D

04•• •
Ca mobilization

N/D

P2Y5

N/D

CRE activation

Hair growth

P2Y10

N/D

Ca mobilization

N/D

lpa 5

GPR87

G 12 / 13 ,

G 12/13

Gs

Adapted from Noguchi K, Herr D, Mutoh T, and Chun J. 2009.
Current Opinion in Pharmacology, 9: 15-23[39]
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expressed in testes and peripheral blood leukocytes and to a lesser extent in pancreas,
spleen, thymus and prostate. High levels of LPA3 expression are observed in prostate,
testes, pancreas, and heart [46], On the other hand, the LPA receptors belonging to the
P2Y family display a more restricted expression pattern [41, 45, 47-49], Almost all
mammalian cells, tissues and organs (excluding the liver) co-express multiple LPA
receptor subtypes of the EDG family, suggesting that LPA receptors may cooperate to
regulate cellular functions [18].
Studies using genetic null mice indicate a degree of functional redundancy between
the LPA receptors [50, 51]. LPA1 knockout mice display 50% perinatal lethality with the
survivors showing abnormal phenotypes such as defective suckling, reduced body size,
craniofacial dysmorphism, and decreased brain mass [52]. On the other hand, LPA2' ‘ are
viable, phenotypically normal and are bom at expected Mendelian ratios. However,
LPAP a and LPA2'/~ double knockout mice are similar to LPAVA mice although the
phenotypes observed are more exaggerated [53], LPA3-null mice exhibit smaller litter
sizes resulting from delayed implantation and embryo crowding [54], While no apparent
abnormalities were observed in LPA4-null mice, mouse embryonic fibroblasts lacking
LPA4 were hypersensitive to LPA-induced cell migration [51]. To the best of our
knowledge, knockout mice for the remaining LPA receptors have not been generated.
Several binding partners have been identified for the LPA receptors that modulate the
specificity, selectivity, and time course of signaling from the receptors [55] (summarized
in Table 1.2). The C-terminal tail of LPAi and LPA2 contain PDZ-binding motifs that
facilitate the recruitment of PDZ domain-containing proteins from the cytosol. PDZ
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Table 1.2 Proteins interacting with LPAi and LPA2 receptors
LPAj receptor
Binding motif

Binding
partner

PDZ-binding
motif

PDZ-RhoGEF
LARG

Functional outcome

•

RhoA activation

RhoGEF
LPA2receptor
Binding motif

PDZ-binding
motif
(distal end)

Zinc finger
binding
motif
(proximal
region)

Binding
partner
NHERF2

Functional outcome

•
•
•

Activation of PLC-P3 signaling pathways
Activation of AKT and ERKs
Linking LPA2 with CFTR to inhibit CFTR
activity

PDZ-RhoGEF
LARG

•

RhoA activation

MAGI-3

•

Activation of RhoA and ERKs

TRIP6

•

Regulation of cell migration through
c-Src/PTPLl -dependent phosphorylation
and dephosphorylation
ERK activation

•
Siva-1
•

Interactions mediate down-regulation of
Siva-1 to promote cell survival
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domain-mediated interactions promote the rapid recycling of endocytosed GPCRs back to
the cell surface. LPAi receptor contains a Class I PDZ-binding motif, H S W , which
allows the interaction of the receptor with PDZ-RhoGEF and Leukemia associated
RhoGEF (LARG). On the other hand, the PDZ-binding motif found in LPA2 receptor,
DSTL, facilitates the binding of Na+/H+ exchanger regulatory factor 2 (NHERF2), PDZRhoGEF, LARG, membrane-associated guanylate kinase with an inverted domain
structure-3 (MAGI-3), NHERF1, and neurabin [55, 56]. In addition, the proximal region
of LPA2 allows for the interaction of the receptor with zinc finger proteins, including
thyroid hormone receptor-interacting protein

6

and the proapoptotic Siva-1 protein [56].

The binding partners of the rest of the LPA receptors are yet to be identified.

1.2.4. Lysophosphatidic acid receptor signaling
LPA receptors couple to heterotrimeric G proteins to modulate the activity of
downstream signaling pathways (Table 1.1 and Figure 1.5). Heterotrimeric G proteins are
composed of three subunits, a, [3, and y, and are categorized into four main subtypes (Gs,
Gi/o, Gq/n, G 12/13) based on the primary sequence similarity of the a-subunit (Ga). The

capability of heterotrimeric G proteins to relay information from GPCRs depends on the
ability of the a-subunit to cycle between an inactive GDP-bound conformation and an
active GTP-bound form. Activation of Ga leads to the dissociation of the a subunit from
the Py subunit, which proceed to regulate downstream molecules [57].
LPAi and LPA2 can couple to Gi/0, Gq/n and G12/13, which signal via downstream
molecules such as Ras, mitogen-activated protein kinase (MAPK), phosphatidylinositol
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Adapted from Mills GB & Moolenar WH. 2003. Nature Reviews Cancer. 3: 582-591
Figure 1.5 LPA receptor-mediated signaling via heterotrimeric G proteins
LPA receptors couple to Gq/n, G,/0 and G12/13 heterotrimeric G-proteins and stimulate the
activation of various downstream signaling pathways. Gq regulates the activity of
phospholipase C which hydrolyzes phosphatidylinositol-bisphosphate (PIP2 ) leading to
Ca mobilization and protein kinase C activation. Gj/0 coupling mediates signaling via
phosphoinositide 3-kinase and Ras-ERK pathway leading to cell migration and survival.
Activation of the G12/13 pathway leads to cytoskeletal remodeling and changes in cell
morphology and migration.
Figure reproduced with permission (Appendix 1)
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3-kinase, phospholipase C, diacylglycerol and Rho to mediate various cellular processes
such as proliferation,

survival, Ca2+ mobilization, migration and cytoskeletal

rearrangement [50]. LPA3 signals via Gi/0 and Gq/n to regulate phospholipase C
activation, Ca2+ mobilization, cyclic adenosine monophosphate (cAMP) production, and
MAPK activation. However, LPA3 does not couple to G 12/13 and is therefore unable to
modulate Rho GTPase-dependent cytoskeletal rearrangement. Both LPA4 and LPA5 can
couple to G 12/13 and Gq/n which in turn stimulate morphological changes such as cell
rounding and stress fiber formation, as well as cAMP accumulation and Ca mobilization
[50]. Unlike the classical LPA receptors of the EDG family, LPA4 and LPA6 have also
been shown to couple to the Gsheterotrimeric G proteins [58].

1.2.5. LPA receptors and cancer
LPA receptors have been implicated in several cancers. Microarray studies
showed decreased LPAi expression in ovarian cancer tissues when compared to benign
control samples. In contrast, LPA2 and LPA3 mRNA levels are dramatically higher in
ovarian tumors [55]. Overexpression of LPA2 is also observed in various other
malignancies including colon and gastric cancer [59]. LPA2-null mice show decreased
tumor incidence and progression in a chemically-induced colon cancer experimental
model [60],
We and others have demonstrated that high levels of LPAi and LPA2 mRNA are
detected in tissue from breast cancer patients [61, 62], Liu et al. examined the
involvement of LPA receptor expression in breast cancer initiation and progression by
generating transgenic mice individually expressing human LPAi, LPA2, or LPA3 . They
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reported that transgenic mice expressing these receptors show a high frequency of lateonset mammary carcinomas with varying degrees of metastatic incidence [63].
Although, LPAi, LPA2 and LPA3 have been implicated to play a role in breast
cancer, to date, studies support the most conclusive roles for LPAi in breast cancer
metastasis. Boucharaba and colleagues showed that overexpression of the LPAi receptor
in a derivative of the MDA-MB-231 breast cancer cells enhances tumor growth and
metastasis of breast cancer cells to bone in an experimental mouse model [64], A follow
up study by this group showed that reduction of LPAi expression using siRNA or
inhibition of LPAi activity by an antagonist (Ki 16425) results in a marked decrease of
bone metastases, suggesting that LPAi receptors are crucial in breast cancer metastasis
[65]. However, the details of the underlying molecular mechanisms by which LPAi
signaling regulates breast cancer invasiveness, required for metastasis, are largely
unknown. We have recently demonstrated that LPAi regulates the migration and invasion
of breast cancer cells by signaling via the small G protein, Ral, and the scaffolding
protein, p-arrestin [61].

1.3. P-arrestins
1.3.1. Introduction to P-arrestins
P-arrestins are ubiquitously expressed proteins that are composed of two isoforms, Parrestinl (arrestin2) and p-arrestin2 (arrestin3) sharing 78% sequence identity [6 6 ]. The
basic structure of P-arrestins constitutes two domains of antiparallel P-sheets with a
connecting hinge region and a short a-helix at the back of the amino-terminal tail [67], A
polar core within the hinge region interacts with phosphorylated residues on the tail of
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GPCRs. The amino-terminal domain is critical in nuclear localization of P-arrestins [68].
In an inactive state, p-arrestins are phosphorylated on serine 412. Dephosphorylation of
serine 412 allows P-arrestins to bind to Src tyrosine kinases and this leads to the
transactivation of the epidermal growth factor receptor and activation of MAPKs [66].
Individual p-arrestinl and p-arrestin2 knockout mice have been generated, while
simultaneously knocking out P-arrestinl and P-arrestin2 resulted in early embryonic
lethality [69, 70]. p-arrestinl-null mice display an overall normal phenotype, although
they exhibit heightened sensitivity towards P adrenergic agonists [69], On the other hand,
lymphocytes from P-arrestin2 knockout mice exhibit impaired migration in response to
stromal cell-derived factor-1, indicating that P-arrestin2 plays a positive regulatory role in
cell motility [71].
Although

p-arrestins

were

originally

discovered

as regulators

of GPCR

desensitization and trafficking, they have since emerged to be involved in the regulation
of several other processes including gene transcription, cell migration, and cancer
metastasis [66, 72].

1.3.2. Classical roles of P-arrestins
P-arrestins are well known mediators of GPCR internalization and desensitization
(Figure 1.6). However, since this aspect of p-arrestin function is not the major focus of
the current study, it is described briefly. P-arrestins regulate GPCR endocytosis via the
interaction of the p-arrestin C-terminus with components of the clathrin-coated pit
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Figure 1.6 P-arrestin-mediated signaling
p-arrestins form signaling complexes to regulate a diverse array of cellular processes. Parrestins regulate GPCR endocytosis and intracellular trafficking by binding to agonistoccupied GPCRs and recruiting proteins such as clathrin and AP-2. p-arrestins also act as
scaffolds for signaling molecules such as components of the MAPK cascade to facilitate
activation of spatially-restricted effectors. Recent findings also implicated P-arrestins in
gene expression by inhibiting signaling from some pathways and enhancing the activity
of other signaling cascades, p-arrestins regulate cell motility by binding proteins that
modulate the actin cytoskeleton such as the actin severing protein, cofilin.
Figure reproduced with permission (Appendix 1)
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machinery including clathrin and the clathrin adapter protein AP-2 [72, 73]. Under nonstimulated conditions, the majority of (3-arrestins are localized in the cytoplasm and are
constitutive! y phosphorylated by the MAPK extracellular signal-regulated kinase 1/2
(ERK1/2), which renders P-arrestins unable to interact with clathrin. Upon agonist
stimulation, P-arrestins are recruited to the plasma membrane and are rapidly
dephosphorylated, allowing them to promote receptor endocytosis [74, 75], Two classes
of GPCRs exist based on their binding affinity for P-arrestins and the duration of the
receptor-arrestin association. The first class of receptors (Class A, eg. LPAi) forms a
transient interaction with p-arrestins that is rapidly resolved, leading to the recycling of
the receptors to the membrane. The second class (Class B, eg. Angiotensin AT jA
receptor) form a more stable complex with p-arrestins that persists during receptor
internalization and endosomal sorting, causing the receptors to be sequestered in
endosomes for a longer period and eventually recycle back to the plasma membrane or
undergo degradation [72], P-arrestins can also regulate the endocytosis of receptors
outside the GPCR family such as transforming growth factor-p (TGF-p) type III receptor
and insulin-like growth factor type 1 receptor [72],
P-arrestins have been shown to regulate GPCR function in cancer. An interaction
between p-arrestin2 and the chemokine receptor CXCR7 has been observed in vivo by
employing fragment complementation assay [76]. This receptor has been previously
shown to promote the growth and metastasis of breast cancer cells in an experimental
mouse model [77]. To determine if P-arrestins regulate CXCR7 in vivo, the individual
halves of a firefly luciferase enzyme were fused to either CXCR7 or P-arrestin2 and
coexpressed in MDA-MB-231 cells. These cells were injected into the mammary fat pads
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of SCID mice to generate orthotopic tumor xenografts followed by a subcutaneous
injection of the small molecule CXCR7 agonist CCX754. Subsequent bioluminescence
imaging revealed an increase in luciferase activity in agonist-treated mice, suggesting that
p-arrestin2 is recruited to CXCR7 and may modulate its activity within an in vivo model
of human breast cancer [76].

1.3.3. p-arrestins as molecular scaffolds
Although the binding of p-arrestins to GPCRs terminates coupling and signaling via
classic heterotrimeric G proteins, an alternate P-arrestin-mediated signaling can be
initiated while the receptor is being desensitized and entering the endocytic pathway [72].
p-arrestins transduce signals by acting as scaffolds for a variety of signaling molecules in
the cytoplasm, including Src, Raf-1, Akt, ERK1/2, JNK3, MDM2 and I kB (Figure 1.6)
[6 8 , 78], Interestingly, the ability of P-arrestins to bind to Src and activate the
downstream MAPKs is implicated in the malignancy of glioblastomas in human patients
[79]. Dephosphorylation of serine 412 on P-arrestins allows p-arrestins to bind to Src
tyrosine kinases, leading to the transactivation of MAPKs [6 6 ]. P-arrestinl is found in a
constitutively phosphorylated (inactivated) state in nonneoplastic human brain tissue
samples, while the majority of the specimens from the glioblastoma patients display
dephosphorylated P-arrestinl by immunohistochemistry [79]. These results suggest that
P-arrestinl signaling via MAPKs may play a role in tumor malignancy.
P-arrestins have been shown to regulate breast cancer cell proliferation by activating
the MAPK pathway [80]. Silencing of p-arrestinl expression in MCF-7 breast cancer
cells blocks phosphorylation of ERK1/2 and c-Jun N-terminal kinases (JNK) and this
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results in the suppression of cell proliferation [80], suggesting a role for P-arrestins in
regulating breast cancer cell growth.
p-arrestins have also been shown to regulate ovarian cancer metastasis, signaling
downstream of endothelin-1 (ET-1) receptors. Rosano et al. demonstrated that p-arrestins
form signaling complexes with Src and Axin that lead to the phosphorylation and
stabilization of P-catenin. Phosphorylated P-catenin has previously been shown to
regulate the transcription of genes involved in cancer cell invasion and metastasis [81,
82], Thus, p-arrestins may play a role in cancer metastasis by controlling the expression
of genes involved in this process.

1.3.4. Role of P-arrestins in tumorigenesis in vivo
To date, three published studies have reported a role for P-arrestins in tumor
metastasis in vivo [83-85]. Colorectal LS-174T carcinoma cells overexpressing wild-type
P-arrestinl metastasize at a significantly higher rate than cells expressing a vector
control, in an orthotopic liver metastasis model using immunodeficient mice [83]. The
overexpression of a p-arrestinl mutant that is unable to bind c-Src (S412D-P-arrestinl) in
these cells greatly inhibits the rate of liver metastasis, suggesting a role for c-Src in p*
arrestin-mediated colorectal cancer metastasis. These results suggest that the interaction
of p-arrestinl with c-Src is critical in the migration and invasion of colorectal cancer cells
in vitro that is needed for their metastatic spread in vivo [83].
A second study examined the role P-arrestins play in providing the appropriate
microenvironment for tumor initiation and progression in vivo [84], Zou and colleagues
generated p-arrestinl and p-arrestin2 transgenic mice using microinjections followed by
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subcutaneous inoculation of Hepal - 6 murine hepatocellular carcinoma cells, or EL4
mouse lymphoma cells. The results show that P-arrestinl transgenic mice display much
earlier macroscopic tumor nodules than p-arrestin2 transgenic and wildtype mice.
Moreover, the xenograft tumors in the P-arrestinl transgenic mice grow more rapidly and
achieve a much greater volume by day 28 post-injection than p-arrestin2 and wildtype
mice. These results are accompanied by an increased number of small blood vessels in parrestinl transgenic mice, indicating that P-arrestinl promotes tumor progression by
increasing blood supply (angiogenesis). Although p-arrestinl transgenic mice did not
show altered levels of pro-angiogenic vascular endothelial growth factor (VEGF) mRNA
expression, the plasma concentrations of secreted VEGF in these mice is markedly
enhanced. The increase in VEGF observed in P-arrestinl transgenic mice appears to have
been released from the extracellular matrix via the action of matrix metalloprotease-9
(MMP-9), since the expression of activated MMP-9 in these mice is increased after the
inoculation of tumor cells. Pharmacological inhibition of phosphoinositide 3-kinase
abrogates p-arrestinl-mediated increase of MMP-9 activity and small tube formation in
HMEC-1 human microvascular cells, indicating that phosphoinositide 3-kinase signaling
pathways play a role in P-arrestinl-regulated MMP-9 activity and angiogenesis during
tumor progression [84].
Finally, Raghuwanshi and colleagues examined the role of p-arrestin2 in tumour
progression and metastasis by using two different mouse models: heterotropic Lewis lung
cancer and tail vein lung injection of wild-type and P-arrestinl''' mice [85], P-arrestinl'''
mice heterotropically injected by Lewis lung cancer cells display a more rapid tumour
growth, an increased number of metastatic tumor nodules in lungs, and a decreased rate
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of survival when compared with (}-arrestin2 /+ mice. Further analysis revealed that
tumors from (5-arrestin2~" mice express elevated levels of the chemokines CXCL1 and
CXCL2 as well as the pro-angiogenic factors H IF-la and VEGF and these events are
accompanied by an increase in the micro vessel density. These chemokines act on the
CXCR2 receptor which couples with Ga.i to activate phospholipase C-mediated signaling.
Previous studies have shown that CXCR2 internalization is delayed in j3-arrestin2' ~mice
while other cellular responses such as G protein activation and respiratory burst were
enhanced [8 6 ], Inhibition of the CXCR2 receptor by a neutralizing antibody resulted in
decreased tumor size in both J3~arrestin2 /' and /3-arrestin2+ mice, although the effect
was less pronounced in (3-arrestin2-deficient mice. Combined together, these results
indicate that p-arrestin2 depletion promotes angiogenesis, tumor growth, and metastasis
via increased production of pro-angiogenic factors [85].

1.3.5. P-arrestins in cancer cell motility
Several studies have indicated a role for p-arrestins in the regulation of cancer cell
motility. For example, in MDA-MB-231 human breast cancer cells, siRNA knockdown
of p-arrestinl, p-arrestin2 or both inhibits basal cell migration through collagen as well as
in response to the peptide ligand for protease-activated receptor (PAR-2), suggesting that
P-arrestins are required for PAR-2 stimulated migration [87],
In cervical cancer HeLa cells, overexpression of P-arrestin2 enhances CXCR-4mediated migration of cells whereas knockdown of P-arrestin2 expression blocked SDF1a-stimulated migration [8 8 ], Similarly, RNAi-mediated silencing of P-arrestin2, but not
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P-arrestinl expression, in T24 bladder cancer cells results in reduced thromboxane
receptor-mediated migration [89].
The details of the underlying mechanisms by which p-arrestins regulate the
cytoskeleton to promote cell motility are largely unknown. One study has shown that Parrestins regulate breast cancer cell motility by binding the actin filament-severing
protein, cofilin, upon activation of PAR-2 [90]. Cofilin-mediated severing of actin
filaments promotes the formation of membrane protrusions at the leading edge of
migrating cells by enhancing the reorganization of existing filaments and generating free
actin barbed ends for the addition of actin monomers to a growing filament. Ligand
mediated PAR-2 activation results in an association of both p-arrestinl and P-arrestin2
with cofilin and a redistribution and colocalization of the p-arrestins and cofilin to
membrane protrusions. Further experiments showed that PAR-2 promotes cofilin
dephosphorylation by activating the cofilin phosphatase chronophin and the cofilin kinase
LIM kinase (LIMK) and the inhibition by LIMK is attenuated by siRNA-mediated
knockdown of P-arrestins. Cofilin, chronophin and LIMK were colocalized with Parrestins at membrane protrusions of ligand-activated cells, suggesting that p-arrestins
may spatially restrict cofilin-induced actin filament severing during PAR-2 regulated
breast cancer cell migration [90],

1.3.6. P-arrestins in nuclear function
Several studies have implicated p-arrestins in the regulation of signaling pathways
that control gene expression including those mediated by ERK1/2, NFkB, p-catenin and
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p53. Moreover, P-arrestins can translocate to the cell nucleus and modulate transcription
[72].
Upon agonist stimulation, endocytosed GPCRs bound to (3-arrestins can form a
complex with ERKs and sequester them in the cytoplasm [78]. However, several
transcription factors in the cytoplasm can get phosphorylated by ERK1/2 and
subsequently translocate to the nucleus to exert their effects on a distinct but lesscharacterized set of genes involved in such events as changes in cell morphology and
motility [78],
P-arrestins also bind to the oncoprotein MDM2, an E4 ubiquitin ligase, to regulate
transcription [6 8 ]. MDM2 inhibits the function of the tumor suppressor protein p53 by
either binding and sequestering p53 or by acting as a ubiquitin ligase to target p53 for
degradation [91]. Upon ligand stimulation of cells, a complex forms in the cytoplasm that
consists of MDM2, p-arrestin and the corresponding receptor, causing the MDM2 to be
sequestered in the cytoplasm. The consequent reduction of MDM2 concentration in the
nucleus results in more abundant p53 levels that promote the transcription of genes
involved in apoptosis [6 8 ],
Another mechanism for P-arrestin-mediated regulation of gene transcription
includes NF- kB, a transcription factor involved in immunity, stress and apoptosis.
Inactive NF- k B dimers are retained in the cytoplasm by I kB cx. Extracellular stimuli
mediate the phosphorylation of IxBa which causes IxBa degradation, allowing the NFkB

to translocate to the nucleus and activate transcription of target genes. P-arrestins

have been shown to bind and stabilize IxBa, which prevents the phosphorylation and
degradation of IxBa, thereby suppressing NF-xB-mediated gene transcription [72], In
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MDA-MB-231 breast cancer cells, overexpression of transforming growth factor-P
receptor III (TpRIII) leads to an increased expression of both basal and TGF-p-induced
IkB cx expression, whereas a mutant TpRIII that is unable to interact with p-arrestin2 fails

to have the same effect [92]. Furthermore, knockdown of p-arrestin2 expression by
siRNA in these cells results in a loss of TpRIII-mediated hcBa expression, further
supporting a role for p-arrestin2 in mediating the suppression of NF kB signaling
downstream of TpRIII [92], Surprisingly, LPA stimulation of NF- kB activation is
impaired in mouse embryonic fibroblast (MEF) cells that are knocked out for P-arrestin2,
but not P-arrestinl, indicating that P-arrestin2 actually positively regulate NF- kB in this
system [93],
Evidence of P-arrestin localization in the nucleus reported by several studies
suggests that p-arrestins may play a more direct role in gene expression [6 8 ]. In cervical
cancer HeLa cells, stimulation of the 8 -opioid receptor, a member of the GPCR family,
leads to the translocation of p-arrestin 1 to the nucleus which promotes the transcription
of p27 and FOS genes which are involved in the regulation of cell proliferation.
Stimulation of 5-opioid receptor activity in human neuroblastoma cells results in a parrestin-mediated induction of p27 gene transcription and inhibition of growth [6 8 ].
A very recent study by Shankar et al. showed that p-arrestins are localized in the
centrosome of MDA-MB-231 breast cancer cells and are involved in the multinucleation
phenotype observed in these cells [94], Centrosomes regulate the microtubule during
interphase and are involved in microtubule-related processes such as cell polarity,
motility and structure. Overexpression of p-arrestinl or P-arrestin2 in MDA-MB-231
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cells reduces the proportion of cells with multiple nuclei while siRNA knockdown of
either P-arrestin in human embryonic kidney (HEK293) cells results in multinucleation
defects [94]. These findings suggest a novel role for P-arrestins in the maintenance of
normal centrosome function.

1.3.7. P-arrestins and small G proteins
The Ras superfamily of small G proteins is composed of over 150 members that are
divided into six subfamilies (Figure 1.7) [95]. Small G proteins function by cycling
between an inactive GDP-bound and an active GTP-bound state (Figure 1.7A).
Activation of small GTPases is facilitated by guanine-nucleotide exchange factors
(GEFs) which catalyze GDP release and allow the more abundant GTP to bind. GTPbound forms of small G proteins then bind to downstream effector proteins to regulate a
diverse array of cellular processes such as growth, survival, differentiation and vesicle
trafficking. GTPase activity is negatively regulated by GTPase activating proteins
(GAPs), which enhance the intrinsic GTPase activity of small G proteins, leading to the
hydrolysis of the bound GTP to GDP (Figure 1.7) [95],
P-arrestins have been implicated in the regulation of small G-proteins such as Arfó,
Rho and Ral. GEFs such as ARNO, a regulator of Arfó activity, associate with p-arrestins
and play a role in P2 adrenergic receptor endocytosis [96]. P-arrestins also regulate the
Rho GTPases, which modulate the actin cytoskeleton [97], RNAi-mediated depletion of
P-arrestinl abrogates RhoA activation and stress fiber formation in response to
stimulation of angiotensin II receptor. These findings establish a role for P-arrestins in
the regulation of the cytoskeleton via Rho small G proteins.

29

Figure 1.7 Ras superfamily of small G proteins
(a) Ras superfamily of GTPases cycle between an inactive GDP-bound and an active
GTP-bound state. Activation is promoted by Guanine exchange factors (GEFs) and
inactivation is enhanced by GTPase activating proteins (GAPs)
(b) The classification of Ras superfamily members.
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P-arrestins also regulate the small G protein Ral, in a Ras-independent manner, by
modulating the activity of Ral-GDP dissociation stimulator (RalGDS), a GEF for Ral. Parrestins can bind and sequester RalGDS in the cytoplasm. Stimulation of chemoatractant
receptors such as fMLP receptors results in the recruitment of P-arrestin to the cell
surface and the release of RalGDS, which activates Ral, leading to cytoskeletal
reorganization of rat basophilic leukemia-2H3 cells [98], Results from our laboratory
show that silencing of both p-arrestinl and p-arrestin2 in MDA-MB-231 cells abolished
LPA-stimulated activation of the small GTPase RalA, suggesting that P-arrestins are
involved in RalA-mediated effects such as the migration and invasion of breast cancer
cells. Furthermore, we observed that the mRNA expression of p-arrestin2 and Ral
GTPases are elevated in advanced stages of patient breast tumors [61].
The activation of the small GTPase Rapl has also been reported to be dependent on
the presence of P-arrestins. In rat RBL-2H3 cells expressing the CXCR2 receptor,
activation of Rapl by keratinocyte-derived chemokine is markedly inhibited by
knockdown of p-arrestin2 expression. However, whether or not P-arrestins regulate Rapl
activity in breast cancer cells, or if P-arrestins signal via Rapl to regulate breast cancer
cell invasiveness is unknown and forms the basis for this study.

1.4. Rapl GTPases
1.4.1. Introduction to Rapl GTPases
Rap GTPases belong to the Ras superfamily of small G-proteins and are composed of
Rapl (A and B) and Rap2 (A, B, and C) subtypes (Figure 1.7B) [99]. RaplA was
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originally identified in a screen for suppressors of the transforming activity of oncogenic
Ras and was independently cloned by another group based on its homology to Ras (50%
sequence similarity) [100, 101]. However, several studies have since revealed that Rapl
can signal independently of Ras activity to regulate various cellular processes including
gene transcription, cell proliferation, cell growth, vesicle trafficking, cadherin-based cell
cell adhesion, integrin-dependent cell-extracellular matrix adhesion, cell polarity and
migration [99, 102-104], Interestingly, RalGDS, a GEF for Ral GTPases, associates with
Rapl with 100-times more affinity than Ras [105].
Activation of Rapl is facilitated by Rap guanine exchange factors (RapGEFs) such as
C3G, Epac, CalDAG-GEF, SmgGDS, PDZ-GEFs, DOCK4, phospholipase Cs, and MrGEF [106] (Figure 1.8). Inactivation of Rapl is promoted by GTPase activating proteins
(GAPs), which include the RapGAP and Spa-1 families [107]. Several of the RapGEFs
are regulated by second messengers such as Ca2+, diacyl glycerol and cAMP, which are
generated in response to extracellular stimuli [103]. Stimulation of several cell surface
proteins, including cell adhesion molecules and receptor tyrosine kinases, regulate Rapl
activity [108], Although one study has shown that Rapl is activated in response to LPA,
thrombin, and endothelin, the mechanisms involved in the regulation of Rapl activity
downstream of GPCRs have not been investigated [109].
RaplA-null mice have been generated by two independent studies [110, 111],
Although the mice are viable and fertile and their immune system appears functional, a
defect in the adhesion to extracellular matrix of spleen and macrophages isolated from
Rapl A''mice was observed. In addition, Rapl A-deficient macrophages exhibit increased
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Figure 1.8 Rapl signaling pathways
Stimulation of cell surface molecules including E-cadherin, receptor tyrosine kinases and
GPCRs leads to the generation of second messengers such as Ca2+ and cAMP which
activate guanine exchange factors for Rapl including RapGRP and DOCK4. Rapl
guanine exchange factors (shown here in pink) facilitate the exchange of GDP for GTP
on Rap 1 thereby activating Rap 1. Activated Rap 1 signals through downstream effectors
such as integrins and rho that regulate such processes as cytoskeletal rearrangement
needed for cell motility. Rapl GTPase activating proteins (shown in green) catalyze the
hydrolysis of GTP for GDP on Rapl thereby inactivating them.
Figure reproduced with permission (Appendix 1).
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random movement, while directional cell migration towards chemokines such as CCL21
is impaired [111]. B-cells isolated from Rap IB knockout mice also display defective
adhesion to the extracellular matrix [112]. In addition, RaplB-rwiW mice show an
impairment in platelet aggregation, endothelial migration, proliferation, MAPK signaling
and neovascularisation [113, 114].

1.4.2. Rapl and Cancer
Rapl, its GEFs and GAPs have previously been implicated in several cancers. A
decrease in Rapl GAP expression is observed in pancreatic cancer, oropharyngeal
squamous cell carcinoma, thyroid cancer, and melanoma [115-118], suggesting a role for
Rapl GAP as a tumor suppressor. Moreover, deficiency of Spal in mice results in the
development of myeloproliferative disorders that mimic chronic myelogenous leukemia
[119].
Rapl activity appears to play opposing roles with respect to cancer cell invasiveness.
In squamous cell carcinoma, overexpression of Rapl GAP promotes cell invasion [120]
and downregulation of Rapl A by siRNA enhances invasiveness [102]. Consistent with
these findings, osteosarcoma cells that express an inactive mutant of DOCK4 are more
invasive than cells expressing wild-type DOCK4 [121]. These studies suggest that Rapl
negatively regulates cancer cell invasion. However, pro-invasive roles for Rapl have also
been reported as loss of Rapl GAP enhances pancreatic cancer invasion and activation of
Rapl promotes invasion and metastasis of prostate cancer cells [115, 122], Thus, it is
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crucial to elucidate the molecular pathways Rapl mediates in order to understand the
contradictory roles Rapl plays in cancer cell invasion.
To date, one study has examined a direct role for Rapl in the regulation of breast
cancer. Expression of constitutively active Rapl A in breast cancer cells promotes cell
invasion [123]. However, the molecular pathways underlying Rapl-mediated breast
cancer cell invasiveness are yet to be elucidated.

1.5. IQGAP1
The multi-functional, actin-binding and scaffolding protein, IQGAP1 has recently
been identified as a binding partner for Rapl in biochemical assays using purified
proteins [124], IQGAP1 was shown to preferentially bind to activated Rapl in vitro,
providing a possible mechanism for the diverse set of cellular processes mediated by
Rapl. IQGAP1 appears to be a negative regulator of Rapl function since overexpression
of IQGAP1 in MCF-7 human breast epithelial cells reduced the amount of fibronectininduced Rapl activity [124], However, the functional role of the IQGAPl-Rapl
interaction in any cell type has not been studied.
IQGAP1 binds to a diverse array of signaling and structural proteins to regulate
various processes including cell polarization, cell motility, cell invasion, cytoskeleton
structure and E-cadherin-mediated cell-cell adhesion (Figure 1.9) [125]. A recent study
has shown that IQGAP1 protein expression is higher in human infiltrating ductal
carcinoma relative to normal breast tissue [126]. In addition, overexpression of IQGAP1
in human MCF-7 breast epithelial cells enhances cell proliferation in vitro and formation
of invasive tumors in vivo [126].
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Figure 1.9 IQGAP1 integrates multiple signaling pathways
Several cell surface molecules signal to IQGAP1 via second messengers including PKC,
Ca , and Ras. IQGAP1 in turn acts through target proteins such as P-catenin, E-cadherin,
MAPK, and small G proteins such as Racl to exert its effect on gene expression, and
cytoskeleton rearrangement needed for cell migration. However, whether or not IQGAP1
functions downstream of any G protein-coupled receptors (eg. LPA receptors) is
unknown.
Figure reproduced with permission (Appendix 1).
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IQGAP1 can signal downstream of several cell surface molecules including the
receptor tyrosine kinase epidermal growth factor receptor and the transmembrane
glycoprotein CD44 to play a role in processes such as cell migration (Figure 1.9) [125].
However, it is unknown if IQGAP1 signals downstream of GPCRs to regulate
organization of the actin cytoskeleton, needed for cell migration and invasion, and will be
addressed in the current study.
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1.6. Rationale and Hypothesis
1.6.1. Rationale
We have recently shown that the simple blood-borne lipid LPA stimulates the
migration and invasion of breast cancer cells, processes required for metastasis, by
signaling via P-arrestin and Ral GTPases [61]. LPA acts via its GPCR, LPAi, to stimulate
the metastasis of breast cancer cells to bone in vivo [64, 65]. However, the underlying
signaling mechanisms that regulate LPA-mediated breast cancer metastasis are largely
unknown. The Ral guanine nucleotide exchange factor, RalGDS, can also function as an
effector of Rapl GTPases, binding the activated (GTP-bound) form of Rapl[105], Rapl
GTPases and their regulatory proteins have been implicated to play a role in various
cancers [102, 115-123], However, it is unknown whether or not Rapl regulates breast
cancer cell migration and invasion. We therefore sought to determine if LPA signals via
Rapl GTPases to modulate the cytoskeleton, necessary for breast cancer cell migration
and invasion (Figure 1.9).
1.6.2. Hypothesis
Rapl positively regulates LPA-stimulated migration and invasion of breast cancer cells
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Figure 1.10 A schematic model showing mechanisms by which LPA signaling
regulates breast cancer cell migration and invasion.
Shown with blue arrows are pathways we have established play a role downstream of
LPAi to regulate breast cancer invasiveness, via (3-arrestins and Ral (Li, Alemayehu et
al., Molecular Cancer Res, 2009). Shown in red are the pathways investigated in the
current study.
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Chapter 2
P-arrestin regulates lysophosphatidic acid-induced human breast cancer cell
invasiveness via Rapl and IQGAP1
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2.1 Introduction
The blood-bome lipid molecule lysophosphatidic acid (LPA) plays a role in a variety
of cancers, stimulating cancer cell proliferation, survival, migration and invasion [ 1 ],
LPA signals via three specific Edg family G protein-coupled receptors (GPCRs), LPA 1.3.
Overexpression of LPAi in breast cancer cells enhances cancer metastasis in a xenograft
model, and this can be blocked upon depletion of LPA] expression [2, 3].
We have recently shown that LPAi stimulates breast cancer cell migration and
invasion by signaling via the GPCR adapter protein p-arrestin and the small GTPase Ral,
a member of the Ras superfamily [4], Ral activity can be regulated by its guanine
exchange factors (GEFs) such as RalGDS and P-arrestin in a Ras-independent manner
[4], Emerging roles for P-arrestins in cancer metastasis in vivo and cancer cell motility in
vitro have been reported [5]. P-arrestins regulate the organization of the actin
cytoskeleton by acting as scaffolds for components of the mitogen-activated protein
kinase cascade and by binding the actin filament-severing protein, cofilin [5]. However,
the underlying signaling pathways by which p-arrestins modulate the cytoskeleton to play
a role in cancer cell motility are largely unknown.
RalGDS can also associate with another small GTPase, Rapl, with 100-times more
affinity than Ras [6 ], Rapl GTPases (composed of A and B subtypes) belong to the Ras
superfamily of small G proteins. Although Rapl was originally discovered as a revertant
of ^-^as-mediated cell transformation, several studies have since demonstrated that Rapl
signals in a Ras-independent manner to regulate various cellular processes including gene
transcription, cell proliferation and growth, vesicle trafficking, cell adhesion, cell polarity
and migration [7, 8 ]. In the past decade, a role for Rapl and its regulators has emerged in
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a variety of cancers, including pancreatic cancer, oropharyngeal squamous cell
carcinoma, thyroid cancer, melanoma and leukemia [9-12]. To date, one study has
implicated a role for Rapl in breast cancer, showing that expression of constitutively
active Rapl A in malignant HMT-3522 T4-2 breast cancer cells results in increased cell
invasion [13]. However, whether or not Rapl expression is altered in patient breast
tumors or whether Rapl plays a role in the regulation of the cytoskeleton to mediate
breast cancer invasiveness is not known.
Rap 1 has been shown to directly associate with the actin-binding scaffolding protein
IQGAP1, which has well established roles in tumor invasion and matrix degradation [14].
The amount of IQGAP1 in human breast tumors and carcinoma is greater than that of
normal tissue, with metastatic MDA-MB-231 cells expressing the highest levels among
breast cancer cell lines [15]. Stable knock-down of IQGAP1 has been shown to result in
the formation of reduced breast tumors in vivo using a xenograft model [15]. IQGAP 1
binds to a diverse array of signaling and structural proteins to regulate various processes
including cell polarization, cell motility, cell invasion, cytoskeleton structure and Ecadherin-mediated cell-cell adhesion [16]. However, the functional role of the IQGAP 1Rapl interaction in any cell type is unknown.
Here we report that the expression of Rapl is significantly increased in human breast
tumor samples. We also found high levels of Rapl in the invasive breast cancer cells in
comparison to weakly invasive or non-invasive cells. We show for the first time that LPA
stimulates Rapl activity in breast cancer cells, but not in non-malignant mammary
epithelial cells, and that LPAi receptors associate with Rapl. Furthermore, we found that
P-arrestin2 complexes with Rapl and IQGAP 1 in breast cancer cells, and we have
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identified a novel mechanism by which (3-arrestin2 regulates LPA-induced breast cancer
cell invasion by signaling via a Rapl/ IQGAP1 pathway.

2.2. Materials and Methods
C ell c u ltu r e -

Cell lines were purchased from American Type Culture Collection

(Manassas, VA) and grown at 37 °C with 5% CO2 . MDA-MB-231 and Hs578T were
cultured in RPMI-1640 (Invitrogen, Burlington, Ontario, Canada). MCF-7 cells were
maintained in Dulbecco’s Modified Eagle Medium (Invitrogen, Burlington, Ontario,
Canada) which was supplemented with insulin (5 jig/ml). Media for all cancer cell lines
was supplemented with 10% (v/v) fetal bovine serum (Sigma). The non-malignant
mammary epithelial MCF-10A cells were grown in Mammary Epithelial Basal Medium
(Clonetics-Cambrex, Guelph, Ontario, Canada), supplemented with BulletKit (CC-3150)
and cholera endotoxin (100 ng/ml) (Sigma Aldrich).
R ea g en ts a n d c o n s tru c ts -

Lysophosphatidic acid (18:1; 1-oleoyl-2-hydroxy-.sn-

glycero-3-phosphate) was purchased from Avanti Polar Lipids (Albaster, AL). YFPtagged Rapl A constructs were received from Dr. Mina Bissell (Berkeley, CA) (16).
Rapl A shRNA containing plasmids were purchased from Origene Technologies
(Rockville, MD). FLAG-tagged LPAi DNA construct was provided by Dr. Gordon Mills
(MD Anderson Cancer Institute, Houston, TX). Myc-tagged IQGAP1 constructs and
siRNA targeting IQGAP1 were supplied by Dr. David Sacks (Boston, Massachusetts)
[14,17].
S ta b le tra n sfectio n s a n d g e n e k n o c k d o w n -

MDA-MB-231 cells were transfected by

electroporation with 25 pg of DNA using Gene Pulser Xcell (Bio-Rad, Mississauga,
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Ontario, Canada) according to the manufacturer’s instructions (250V and 950 pF) as
previously described [4], Two days after electroporation, heterogeneous populations of
cells transfected with YFP-tagged Rapl A or FLAG-LPAi were selected using G418 (750
pg/ml). For knockdown of Rapl A, four different shRNA constructs targeting Rapl A
were individually transfected into MDA-MB-231 cells by electroporation. Cells stably
transfected with Rapl A shRNA were selected by culturing in media containing
puromycin (1 pg/ml) and 3 clones showing the best knockdown (by Western blot
analysis) were pooled together and used for subsequent experiments. To silence IQGAP1
expression, a Bio-Rad microporator was used to transfect

6

x 105 cells with either a

scrambled control or an siRNA construct targeting IQGAP1 (both cloned in pSuper
expression vector) according to the manufacturer’s instructions ( 1400 Volts, 10 ms pulse
width). Stable cell lines were selected by culturing in puromycin (1 pg/ml) and clones
with the best knockdown were chosen for the rest of the experiments. Sequences for the
Rapl A shRNA constructs used are listed in the Table below. The siRNA against
IQGAP1 targets the 4959-4977 region of the IQGAP1 mRNA with +1 representing the
first nucleotide of the first codon.
Table 2,1 Rapl A shRNA constructs used in study
Construct
Rap 1A shRNA-1
Rapl A shRNA-2

Sequence
GCCAACAGTGTATGCTCGAAATCCTGGAT
CTATT ACAGCTCAGTCCACGTTTAACGAC

Quantitative real-time PCR - An array of cDNA samples from tissue at different
stages of breast cancer (0-IV) were purchased from Origene Technologies. Stage 0
samples represent tissues taken from patients diagnosed with breast cancer, but from
normal regions (www.origene.com). The cDNA samples were pre-normalized by the
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manufacturer using P-actin expression. Chromo4 Real-time Thermal Cycler (Bio-Rad)
was used to perform real-time PCR on the cDNA samples using SYBR-Green 1 (Bio
Rad) for product detection as previously described [4]. The forward and reverse primer
sequences used for RaplA were 5'-ACAGGACCTGAGGGAACAGA-3' and 5'CCCTGCTCTTTGCCAACTAC-3' respectively. RaplA gene expression in breast
cancer tissue was expressed relative to Stage 0 samples. One-way ANOVA statistical
analysis was performed on the log-transformed relative expression values and a
Dunned’s Multiple Comparison post-hoc test was conducted.
Co-immunoprecipitation and immuno-blots - Rapl expression in cell lines was
examined using a rabbit anti-Rapl antibody (1:500, Santa Cruz Biotechnology, Santa
Cruz, California). Equal loading of the samples was verified by checking p-actin
expression (Rabbit antibody, 1:2000, Sigma). Co-immunoprecipitation experiments were
conducted as previously described [4], To investigate the interaction between LPAi
receptor and Rapl, MDA-MB-231 cells stably expressing FLAG-tagged LPAi receptors
were transiently transfected with myc-tagged RaplA constructs using Lipofectamine
2000 (Invitrogen, Burlington, Ontario, Canada) according to the manufacturer’s
instructions. Forty-eight hours after transfection, cells were serum-starved for 4 hours and
stimulated with 10 pM LPA for the specified times. Cell lysates were then subjected to
co-immunoprecipitation assays. Receptors were pulled down at 4 °C for 12-16 hrs using a
rabbit anti-FLAG antibody (Sigma) and protein G-sepharose beads (Amersham
Bioscienses, Piscataway, NJ) from 500 pg of the proteins. The unbound proteins were
then washed away and the co-immunoprecipitated proteins were subjected to SDSPAGE. A mouse anti-myc antibody (1:1000) was used to detect the co-
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immunoprecipitated myc-RaplA. To examine if Rap 1 and IQGAP1 interact, the MDAMB-231 cells stably expressing YFP-tagged RaplA were serum-starved for 4 hours and
stimulated with 10 pM LPA for the indicated times. Lysates were collected from cells
and subjected to co-immunoprecipitation studies by using anti-GFP antibody followed by
Western

blot

studies

employing

rabbit

anti-IQGAPl

antibody

(Santa

Cruz

Biotechnology, Santa Cruz, California). Similarly, to examine the interaction between
IQGAP1 and p-arrestin2, endogenous IQGAP1 was pulled down using rabbit antiIQGAPl antibody and probed for p-arrestin2 in a subsequent Western blot analysis
(using a mouse monoclonal antibody, 1:300). To investigate the interaction between
Rapl and p-arrestin2, endogenous Rapl was immunoprecipitated using a rabbit antiRapl antibody (Santa Cruz Biotechnology, Santa Cruz, California) and subsequent
Western blotting was performed to detect p-arrest in2.
Rapl activation assay- A Rapl-activation assay kit was purchased from Upstate
Biotechnology (Lake Placid, NY) and assays were performed in accordance with the
manufacturer’s instructions. Briefly, cells were serum starved for 4 hours and stimulated
with 10 pM LPA for the indicated times. Cells were then lysed and active (GTP-bound)
Rapl was pulled down using agarose beads conjugated to RalGDS-RBD. The beads were
then washed to remove unbound proteins and subjected to Western blot analysis using a
rabbit anti-Rapl antibody that recognizes RaplA and Rap IB (1:500, Upstate
Biotechnology, Lake Placid, NY) and visualized by chemiluminescence. Equal loading
was confirmed by examining the total Rapl levels in each sample. For positive controls
of the assay, GTPys was added to cell lysates prior the pull-down assay.
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L iv e c e ll im a g in g -

Cells were stably transfected with YFP-tagged RaplA constructs

by electroporation and were plated on 35 mm glass-bottomed culture dishes (MatTek,
Ashland, Massachusetts). After 4 hours of serum starvation, cells were stimulated with 10
pM LPA and imaged with Olympus FluoView FVlOi confocal laser scanning
microscope.
Im m u n o sta in in g

- MDA-MB-231 cells were serum starved for 4 hours and

stimulated with 10 pM LPA (times indicated in figure legends). Cells were then fixed and
permeabilized with 3.7% paraformaldehyde and 0.2% Triton-X-100. Endogenous
IQGAP1 was labeled using a rabbit anti-IQGAPl antibody (1:500, Santa Cruz
Biotechnology, Santa Cruz, California) followed by anti-rabbit AlexaFluor-568 antibody
(1:250, Molecular Probes, Eugene, OR). Filamentous actin was stained with AlexaFluor555-conjugated phalloidin (1:100, Molecular Probes). Nuclei were labeled using 0.1%
Hoechst 33258 (Invitrogen, Burlington, Ontario, Canada).
Three d im e n sio n a l

(3D) in vasion assays - 3D invasion assays were conducted as

described previously [4, 18]. Cells were plated in a 1:1 dilution of phenol-free Matrigel
and culture medium at 2.5 x 106 cells/mL on Matrigel-coated 35 mm glass-bottomed
culture dishes (MatTek, Ashland, Massachusetts). Complete culture media was overlaid
on cells, and cells were then maintained for 5 days. Cell colonies were scored in a blinded
manner as either stellate or spheroidal after growth in Matrigel. Stellate colonies were
characterized by one or more projections from the central sphere of cells.
C ell m igration a n d invasion a ssa ys

- Transwell chamber migration and invasion

assays were performed as detailed previously [4], Millipore filters

(8

pm pores) were

placed in a 24-well plate containing either serum free media, 10 pM LPA in serum-free

61

media, or 10% FBS. For invasion assays, filters were coated with 50 pi of diluted
Matrigel in serum-free RPMI 1640 (9.4 mg/ml stock, BD Biosciences). After serum
starvation for 4 hours, 40,000 cells were placed on top of the filters, and migration and
invasion assays were conducted for 20 hours. The top of the filter was then scraped to
remove cells that did not migrate. Cells were then fixed using a solution of 20% acetone
and 80% methanol and nuclei were stained using 0.1% Hoechst 33258 (Invitrogen,
Burlington, Ontario, Canada). Ten random fields on the filter were imaged using an
Olympus IX-71 inverted microscope and the number of cells (nuclei) that migrated was
counted. Relative migration was expressed as a percentage of control cells (Scrambled
control cells for knockdown experiments in MDA-MB-231 cells or non-transfected
MCF-10A cells to compare with myc-RaplA-expressing MCF-10A cells).
Scratch assays fo r cell motility - MDA-MB-231 cells were seeded into a 12-well
dish in RPMI 1640 supplemented with 10% FBS and allowed to grow to confluency.
Cells were then serum-starved in RPMI for 4 hours and scratched with sterile pipette tips
followed by treatment with 10 pM LPA in serum-free medium. Cells were allowed to
migrate into the scratch for 16 hours and visualized every 10 minutes using an IX-81
inverted microscope (Olympus). Distance travelled (in pm) was then measured after 16
hours, in duplicates for each condition, by using ImagePro software (Media Cybernetics).
Statistical analysis - Student’s t-test or one-way ANOVAs with a Dunnet multiple
comparison post hoc test were used to assess statistical significance with GraphPad Prism
software (GraphPad Software Inc.). Differences with p < 0.05 were considered
statistically significant.
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2.3. Results
2.3.1. Rapl expression is elevated in patient breast tumors and
invasive breast cancer cells
We examined whether or not the expression of Rapl is altered in breast cancer
compared to normal conditions. Quantitative real-time PCR was conducted on a cDNA
array of 48 samples from breast cancer tissue at stages 0-IV of the disease. Rapl A
mRNA was significantly higher in stages I-IV of primary tumor samples compared to
expression in the stage 0 samples (Figure 2.1, p<0.01).
We also compared the expression of Rapl proteins in three well-established human
breast cancer cell lines (MCF-7, MDA-MB-231, and Hs578T) with the non-malignant
mammary epithelial (MCF-10A) cells by Western blot analysis. Higher levels of Rapl
were observed in the invasive Hs578T and the highly invasive MDA-MB-231 breast
cancer cells relative to the expression in the weakly invasive MCF-7 breast cancer cells,
as well as the non-tumorigenic MCF-10A mammary epithelial cell line (Figure 2.2A,
p<0.05). We next examined Rapl expression in the MCF-10A cell line series of isogenic
cells which display a stepwise progression from a normal breast epithelial towards a more
aggressive cancer phenotype [19]. Western blot analysis showed that Rapl protein
expression is elevated in MCF-10A ductal carcinoma in situ (MCF-10A DCIS,
tumorigenic) cells when compared to the parental MCF-10A cells (Figure 2.2B, p<0.05).
The MCF-10A DCIS cells are able to yield in situ carcinoma, while MCF-10A Met cells
have been shown to form lung metastasis in studies employing xenograft mouse models
[19].
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Figure 2.1 Rapl expression in breast cancer tissue
Breast cancer tumors from stages (I-IV) of the disease express higher levels of Rapl A
mRNA compared to stage 0 samples as determined by quantitative real-time PCR. Data
points shown are log-transformed values of relative mRNA expressions compared to
average expression in stage 0 samples. Levels of p-actin were used to pre-normalize
samples by the manufacturer, a, p<0.01, compared to stage 0.
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Figure 2.2 Rapl expression in breast cancer cells
A.The invasive MDA-MB-231 and Hs578T breast cancer cell lines express elevated
levels of Rapl protein relative to the non-invasive MCF-7 breast cancer cells and the
non-malignant MCF-10A mammary epithelial cells. Endogenous expression of Rapl in
each cell line was determined by Western blot analysis. Graphs are expressed relative to
the Rapl protein expression in MCF-lOa cells. Blot is representative of three
independent experiments. *, p<0.05. B. Higher levels of Rapl protein expression are
detected in MCF-10A ductal carcinoma in situ (MCF-10A DCIS) cells compared to the
non malignant MCF-10A cells. A representative blot from three independent experiments
is shown. *, p<0.05
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2.3.2. Rapl GTPases are activated by LPA and associate with LPAi
in breast cancer cells
To determine whether or not LPA stimulates Rapl activity in cancer cells, the content
of active (GTP-bound) Rapl was measured through its ability to strongly bind to its
effector protein RalGDS, more specifically, the Rapl-binding domain of RalGDS
(RalGDS-RBD). Cells were stimulated with 10 pM LPA, as determined from doseresponse studies that we have previously reported [4]; this concentration of LPA has also
been used in other similar studies [20, 21]. All assays were done using serum-starved
cells to eliminate the effects of LPA in serum. The amount of active Rapl was
significantly increased in MDA-MB-231 cells upon stimulation with LPA (Figure 2.3A).
In contrast, LPA failed to activate Rapl in non-malignant mammary epithelial MCF-10A
cells (Figure 2.3B).
We also found that LPA stimulated the association of Rapl A with LPAi in MDAMB-231 cells stably expressing the receptor (Figure 2.4). This suggests that LPA
receptors may regulate Rapl activity by interacting with Rapl, in response to LPA.

2.3.3. Knockdown of Rapl expression blocks breast cancer migration and invasion
In order to validate a role for Rapl signaling in breast cancer cell migration and
invasion, we depleted Rapl A expression in breast cancer cells. MDA-MB-231 cells
stably expressing four individual shRNA constructs against Rapl A were generated. The
two constructs that gave the best knockdown were selected and 2-3 clones per shRNA
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Figure 2.3. Rapl is activated by LPA in breast cancer cells, but not non-malignant
mammary epithelial cells
A. MDA-MB-231 cells were serum-starved for 4 hours and stimulated with 10 pM LPA
for the indicated times. Cells were then lysed and activated Rapl was pulled down using
RalGDS-RBD-conjugated beads and immunoblotted using a rabbit anti-Rapl antibody.
Total Rapl expression in 100 pg of protein was examined to verify equal loading of
samples. Representative blot from four independent experiments is shown. B. MCF-10A
cells were stimulated with 10 pM LPA for 15 minutes and Rapl activation was
determined. Blot is representative of three independent experiments.
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Figure 2.4. LPA stimulates Rapi to associate with LPAi in breast cancer cells
MDA-MB-231 cells stably expressing Flag-LPAi receptors were transfected with myctagged Rapi A. Serum-starved cells (4 hours) were stimulated with LPA (10 pM) for the
indicated times and lysates were subjected to immunoprecipitation with an anti-Flag
polyclonal antibody. Myc-tagged Rapi was subsequently detected by immunoblotting
with an anti-myc monoclonal antibody. Blot is a representative of two independent trials.
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construct were pooled and used for subsequent studies (shRNA-1 and shRNA-2).
Depletion of Rapl protein expression was verified by Western blot analysis (Figure
2.5A).
Knockdown of Rapl A in MDA-MB-231 cells significantly reduced LPA-mediated
breast cancer cell migration by Transwell chamber assays, when compared with cells
expressing scrambled shRNA controls (Figure 2.5B). Consistent with these observations,
scratch assays showed that LPA-stimulated MDA-MB-231 cell motility was reduced in
cells upon RaplA depletion (Figure 2.6). Stable expression of RaplA shRNA did not
affect

cell

viability

as

determined

by

3-(4,5-dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium bromide (MTT) assays (Figure 2.7).
The effects of RaplA knockdown on breast cancer cell invasion was examined by
three-dimensional (3D) cell invasion assays using a reconstituted extracellular matrix
(Matrigel) that mimics the in vivo micro-environment [18]. A marked reduction in the
number of stellate colonies was observed in MDA-MB-231 stable cell lines expressing
RaplA shRNA (Figure 2.8A). These cells did not invade into the surrounding matrix,
but rather formed spherical organoids similar to those formed by the non-malignant
MCF-10A cells [4], To verify the viability of cells cultured under these conditions, the
nuclei were stained and visualized by confocal microscopy. The results show that the
spheroids were composed of multiple nuclei with intact structures (Figure 2.8B).
Since Rapl expression is higher in the metastatic MDA-MB-231 cells compared to
the non-malignant mammary epithelial MCF-10A cells (Figure 2.2A), we expressed
RaplA in MCF-10A cells, which are non-motile [4], and determined their ability to
migrate. We found that the stable expression of Rapl A stimulated these cells to migrate
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Figure 2.5. Rapl A levels regulate breast cancer cell migration
A. Knockdown of Rapl protein expression in MDA-MB-231 cells stably expressing two
separate Rapl A shRNA constructs is verified by Western blot analysis. Densitometric
analysis shows significantly lower levels of Rapl expression in Rapl A shRNA
expressing cells. A representative blot from five experiments is shown. *, p<0.05. B.
Migration of Rapl-depleted MDA-MB-231 cells towards 10 pM LPA is significantly
inhibited as seen byTranswell chamber assays. Graphs represent the mean relative
percentage migration of cells relative to cells expressing scrambled control from seven
independent experiments. *, p<0.05.
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Figure 2.6. Depletion of endogenous RaplA inhibits breast cancer cell motility
Depletion of RaplA expression significantly blocks scratch closure of MDA-MB-231
cells in response to LPA treatment. Cells that were grown to confluency were serum
starved for four hours and scratched with a sterile pipette tip. Cells were then placed in
media containing 10 pM LPA and allowed to migrate into the scratch for 16 hours and
visualized using an DC-81 microscope. Bars represent the mean distance travelled (in pm)
after 16 hours of culturing in LPA (in pm) from four experments. *, p<0.05, scale bar, 10
pm.
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Figure 2.7 Knockdown of RaplA by shRNA does not affect cell viability
MDA-MB-231 cells stably expressing scrambled shRNA or shRNA targetting RaplA
were subjected to MTT cell viability assays. Absorbance was measured at 575 nm and a
reference reading at 750 nm. The columns represent mean absorbance from three
independent experiments.
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Figure 2.8 Depletion of endogenous RaplA in breast cancer cells inhibits formation
of invasive stellate structures
A. Phase contrast images show that MDA-MB-231 cells expressing RaplA shRNA and
suspendend in matrigel display significantly reduced levels of invasive stellate structures
relative to cells expressing scrambled control. Images are representative of five
independent experiments, scale bar 40 pm. Colony shape was scored as being either
stellate or spheroidal after 4 days of growth in Matrigel and stellate structure formation
was expressed as a percentage of the total number (stellate and spheroid) of colonies. *,
p<0.05. B. MDA-MB-231 cells expressing RaplA shRNA show spheroid structures
containing intact nuclei (stained with 0.1% Hoechst 33258) after 5 days of culturing in
matrigel. Images were taken using confocal microscopy. Bar, 20 pm.
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towards 10% serum, but not towards LPA (Figure 2.9). This indicates that RaplA
expression can promote the acquisition of a motile phenotype in breast epithelial cells.

2.3.4. Rapl localizes in membrane ruffles and retraction fibers in
LPA-treated breast cancer cells
Cytoskeletal rearrangement is a critical component of cell migration and invasion. We
have previously shown that LPA stimulates MDA-MB-231 cells to undergo rapid and
extensive cytoskeletal reorganization [4], To visualize changes in RaplA localization in
response to LPA stimulation, YFP-tagged RaplA proteins were stably expressed in
MDA-MB-231 cells and imaged in real-time by live cell confocal microscopy. Cells
grown under serum-free conditions were stimulated with LPA. In the absence of LPA
treatment, the majority of RaplA is present in the cytoplasm. Within 5 minutes of LPA
stimulation, YFP-RaplA localized to membrane ruffles and retraction fibers. RaplA also
partially co-localized with filamentous actin, which is visualized by staining of fixed
YFP-Rap 1A-expressing cells with fluorescent-tagged phalloidin (Figure 2.10). These
results indicate that RaplA may play a role in LPA-stimulated breast cancer cell
cytoskeletal-rearrangement.

2.3.5. P-arrestin2 associates with Rapl and IQGAP1
We have recently shown that LPA-stimulated breast cancer cell migration and
invasion are mediated by p-arrestin, signaling via Ral GTPases, and that the mRNA
levels of P-arrestin2 are elevated in advanced stages of human breast cancer [4], Since
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Figure 2.9 RaplA overexpression in MCF-10A cells results in enhanced cell
migration
A. MCF-10A cells stably expressing myc-RaplA show increased levels of migration
towards 10% serum when compared to non-transfected cells by Transwell chamber
assays. Migration is expressed as a percentage relative to the migration of the parental
MCF-10A cells towards serum from two independent experiments. B. Expression of
myc-Rapl A was verified by Western Blot using anti-myc monoclonal antibody.
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Figure 2.10. RaplA localizes to membrane ruffles and retraction fibers in response
to LPA stimulation.
A. MDA-MB-231 cells stably expressing YFP-tagged RaplA were serum starved for 4
hours and stimulated with 10 pM LPA. Representative confocal micrographs from three
independent experiments are shown. B. YFP-Rap 1A cells that were stimulated with LPA
for the indicated times were fixed and filamentous actin (F-actin) was stained with
Phalloidin conjugated to Alexa-Fluor-546 (red) and the nuclei were stained with 0.1%
Hoechst 33258 dye (blue). Scale bar, 20 pm.
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RaplA GTPases can bind the RalGEF, RalDGS, a binding partner for P-arrestin2
[22], we sought to determine if Rapl also associates with P-arrestin2. Our results show
that endogenous Rapl interacts with endogenous P-arrestin2 in the absence of agonist,
and this association was significantly increased upon LPA stimulation and persisted after
15 minutes of agonist treatment (Figure 2.11 A). We then determined whether or not
knockdown of P-arrestin2 had an effect on Rapl activation in MDA-MB-231 cells. The
amount of GTP-Rapl was significantly increased in response to LPA stimulation in cells
stably expressing scrambled control. In contrast, we did not observe induction of Rapl
activity by LPA treatment in MDA-MB-231 cells stably expressing shRNA against Parrestin2 (Figure 2.1 IB). Taken together, these data indicate that LPA stimulates Rapl
activity via a p-arrestin2-dependent mechanism in breast cancer cells.
Purified Rapl has been shown to bind the actin scaffolding protein, IQGAP1 [14],
that has been implicated in the regulation of breast cancer cell migration and invasion
[17]. We therefore examined whether or not Rapl binds IQGAP1 in breast cancer cells.
We found that IQGAP1 constitutively associates with RaplA in MDA-MB-231 cells
using co-immunoprecipitation studies and this interaction was not altered upon LPA
stimulation (Figure 2.12A). We also observed that endogenous IQGAP1 co-localized
with YFP-RaplA in MDA-MB-231 cells at the plasma membrane by confocal
microscopy (as indicated by yellow in overlay), in the absence of LPA. Upon stimulation
with LPA, we observed partial co-localization of both proteins in cytoskeletal structures
(Figure 2.12B).
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Figure 2.11. ß-arrestin2 regulates Rapl activity in breast cancer cells
A. MDA-MB-231 cells were serum-starved for 4 hours and stimulated with LPA (10
pM) for the indicated times. Lysates were isolated and subjected to coimmunoprecipitation assays. LPA stimulated association of endogenous Rapl with
endogenous ß-arrestin2. Densitometrie analysis of protein expression was performed and
the association of Rapl and ß-arrestin2 was expressed relative to unstimulated-cells. A
representative blot from four independent experiments is shown. *, p<0.05. B. Depletion
of ß-arrestin2 in breast cancer cells blocks LPA-induced Rapl activation. MDA-MB-231
cells stably expressing either scrambled shRNA or ß-arrestin2-targeting shRNA were
serum starved for 4 hours and stimulated with 10 pM LPA. Cells were then lysed and
activated Rapl was pulled down. Densitometrie analysis was performed and Rapl
activation level was expressed relative to Rapl activity in the corresponding 0 time cells.
A representative blot from three independent experiments is shown. *, p<0.05.
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Figure 2.12. Rapl interacts with IQGAP1 in breast cancer cells
A. MDA-MB-231 cells stably expressing YFP-RaplA were serum-starved for 4 hours
and stimulated with LPA (10 pM) for the indicated times. Lysates were isolated and
subjected to co-immunoprecipitation assays with an anti-GFP monoclonal antibody and
endogenous IQGAP1 was detected with an anti-IQGAPl polyclonal antibody. A
representative blot from three independent experiments is shown. B. Cells stably
expressing YFP-tagged Rapl A were serum starved for 4 hours and stimulated with 10
pM LPA for the indicated times. Cells were then subjected to immunofluorescent
staining for endogenous 1QGAP1 (red) and nuclei were stained with 0.1% Hoechst33258
dye (blue). Images were then captured using confocal microscopy. Areas of co
localization between YFP-RaplA and endogenous IQGAP1 are seen as yellow. Bar, 20
pm.
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We next sought to determine whether p-arrestin2 may regulate LPA-induced
cytoskeletal re-arrangement required for cell invasiveness by interacting with IQGAP1.
We discovered that endogenous P-arrestin2 constitutively associated with endogenous
IQGAP1 in MDA-MB-231 cells and that stimulation of cells with LPA did not
consistently alter the interaction between proteins (Figure 2.13A). Consistent with these
observations, we discovered partial colocalization of IQGAP1 and P-arrestin2 in LPAstimulated MDA-MB-231 cells (Figure 2.14).
To further characterize the interaction between p-arrestin2 and IQGAP1, and to
determine which domain of IQGAP1 interacted with P-arrestin2, HEK293 cells were
transiently co-transfected with Flag-tagged P-arrestin2 and various myc-tagged IQGAP1
constructs. We found that the N-terminus of IQGAP1 interacts with p-arrestin2 (Figure
2.13B). However, absence of the region that includes the IQ domain (AIQ, amino acids
717-916) in IQGAP1 abrogated the interaction between IQGAP1 and p-arrestin2,
indicating that the IQ domain may be important for this association. Interestingly, the IQ
domain has been previously shown to be responsible for the interaction of IQGAP1 with
Rapl [14].
IQGAP1 has been shown to associate with various small GTPases such as cdc42
and Racl [23]. Since p-arrestins have been shown to signal via RalGTPases, we
determined whether or not RalA binds IQGAP1. We found that unlike Rapl, GFP-RalA
does not co-immunoprecipitate with endogenous IQGAP1 in MDA-MB-231 cells (Figure
2.15). This indicates that the interaction of IQGAP1 is specific to a subset of small
GTPases such as Rapl, as demonstrated here, and Racl and cdc42 [23].
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Figure 2.13. Endogenous |3-arrestin2 associates with IQGAP1 in breast cancer cells
A. p-arrestin2 associates with IQGAP1 in breast cancer cells and LPA does not modulate
the degree of association. Serum-starved MDA-MB-231 cells (4 hours) were stimulated
with LPA (lOpM) for the indicated times. Immunopreceipation assays were performed
on lysates using a rabbit anti-IQGAPl antibody and endogenous P-arrestin2 was detected
using a monoclonal anti-P-arr2 antibody. A representative blot from three independent
experiments is shown. B. The N-terminal domain of IQGAP1 interacts with P-arrestin2.
HEK293 cells were transfected with Flag-P-arrestin2 and either full- length myc-tagged
IQGAP1 or myc-tagged mutants of IQGAP1 (N-terminal domain or IQGAP1 missing the
IQ domain). Cells were lysed and subjected to immunoprécipitation using a rabbit anti
Flag antibody and myc-tagged IQGAP1 expression was observed using a monoclonal
anti-myc antibody. Blot is a representative of three independent experiments.
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0-arrestm2
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Overlay

Figure 2.14. P-arrestin2 and IQGAP1 co-localize in LPA-stimulated breast cancer
cells
MDA-MB-231 cells were serum-starved for 4 hours and stimulated with LPA (10 pM)
for the indicated times. Cells were then subjected to immunofluorescent staining for
endogenous IQGAP1 (red) and endogenous P-arrestin2 (green). Nuclei were stained with
0.1% Hoechst33258 dye (blue). Images were then captured using confocal microscopy.
Bar, 20 pm. Areas of co-localization between endogenous IQGAP1 and endogenous parrestin2 are seen as yellow.
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Figure 2.15. IQGAP1 does not interact with RalA in breast cancer cells
MDA-MB-231 cells were transiently transfected with GFP-RalA and serum starved for 4
hours. Cells were treated with 10 pM LPA for the indicated times and subjected to coimmunoprecipitation with an anti-GFP monoclonal antibody. Endogenous IQGAP1 was
detected using an anti-IQGAPl rabbit antibody. The blot is a representative of three
independent experiments.
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2.3.6. LPA-induced breast cancer cell migration and invasion is
mediated by IQGAP1
Since the N-terminus of IQGAP1 was found to interact with P-arrestin2, we then
aimed to determine whether or not the N-terminus functions in a dominant negative
capacity to block LPA-induced breast cancer cell invasiveness. Expression of N-terminus
of IQGAP1 in MDA-MB-231 cells significantly blocked migration of cells towards LPA
and towards media supplemented with 10% serum (Figure 2.16A). IQGAP1 N-terminus
also displayed reduced invasion towards 10% serum, whereas invasion towards LPA was
not altered. Therefore, expression of the N-terminus of IQGAP1 appears to have a
dominant negative effect on the migration of breast cancer cells towards 10% serum, but
not LPA and invasion towards both 10% serum and LPA.
In order to validate the role of IQGAP1 in LPA-mediated breast cancer invasiveness,
we depleted endogenous IQGAP1 expression by stably expressing siRNA against
IQGAP1 in MDA-MB-231 cells. Our results show that depletion of IQGAP1 in breast
cancer cells led to a decrease in breast cancer invasion towards LPA and 10% serum,
when compared to the scrambled control (Figure 2.16B). These results indicate that
IQGAP1 is a novel signaling molecule implicated in LPA-mediated breast cancer cell
invasion.
2.4. Discussion
In this study, we have identified a novel interaction between LPAi and RaplA
GTPases, and show that LPA can stimulate Rapl activity via p-arrestin2 in breast cancer
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Figure 2.16 IQGAP1 regulates migration and invasion of breast cancer cells.
A. MDA-MB-231 cells were transiently transfected with either a vector control or the Nterminal domain of IQGAP1 for 48 hours. Transwell migration and invasion assays were
performed after 4 hours of serum-starvation. Overexpression of the IQGAP1 N-terminus
significantly blocked migration of cells towards LPA (10 pM) and 10% serum and
invasion towards 10% serum. Mean was calculated from four independent trials. *p<
0.05. B. MDA-MB-231 cells that were stably knocked down for IQGAP1 expression
were serum starved for 4 hours and subjected to Transwell invasion assays towards 10
pM LPA. Results represent data from three independent experiments. *, p<0.05.
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cells, to thereby regulate cell migration and invasion. Additionally, we have identified
novel interactions between Rapl and P-arrestin2 as well as IQGAP1, and we propose that
LPA may signal via P-arrestin2/Rapl/IQGAPl to regulate breast cancer invasiveness.
Cancer cell migration and invasion are critical steps in the metastasis of breast cancer.
The small GTPase Rapl has been shown to elicit both pro- and anti-invasive phenotypes
depending on the cancer type [8, 13, 24-27], although the molecular mechanisms by
which this occurs are not well defined. Few studies have examined a role for Rapl in
breast cancer. A germ-line polymorphism in the Sipa-1 gene, a Rapl GAP, has been
associated with aggressive metastatic phenotype in a mouse breast cancer model system
[28], A recent publication by Itoh et al. showed that the activity of endogenous Rapl in
malignant HMT-3522 T4-2 cells is higher than the corresponding SI non-malignant cells.
Using three-dimensional morphogenesis assays, the authors showed that T4-2 cells
expressing a dominant negative mutant of Rapl form organized acinar structures, with
the correct polarity, compared to the vector-expressing control cells which display highly
disorganized apolar structures. This study also demonstrated that constitutively active
Rapl (Rapl V12)-expressing T4-2 cells are more invasive in vitro and form larger
tumors with higher grade of malignancy in vivo than cells expressing the control vector
[13]. However, in large part, a role for Rapl signaling in breast cancer is unknown.
We found that Rapl A mRNA is aberrantly expressed in breast cancer tumors of
patients at stages I-IV of the disease compared with Stage 0 samples, which comprise of
matched normal tissue from patients. This indicates that Rapl may be implicated in
tumourigenesis, even when the tumors have not spread to the node (Stage I) as well as
when tumors metastasize (Stages II-IV). We observed an increase in Rapl protein levels
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in invasive breast cancer cells (MDA-MB-231 and Hs578T cells), in contrast to the non
invasive MCF-7 cells or non-malignant MCF-10A cells. We found that Rapl protein
expression is higher in MCF-10A DCIS and the metastatic variant (MCF-10A Met)
compared to the parental MCF-10A cells. These results imply that the activity or function
of Rapl may be altered in cancer cells. Interestingly, LPA only induced Rapl activity in
the highly metastatic MDA-MB-231 cells and not in the non-malignant MCF-10A cells,
although

these

cells

express

endogenous

Rapl.

These results

suggest

that

chemoattractants such as LPA may only stimulate Rapl in tumor cells. Conversely, we
observed that stable expression of Rapl A in normal mammary MCF-10A cells stimulated
their migration towards media with 10% serum; these cells are normally non-invasive and
non-migratory [4]. However, the RaplA-expressing MCF10A cells did not migrate
towards LPA in serum-free media, indicating that other factors in the serum were
necessary to induce the migration response.
We found that LPA induction of Rapl activity in MDA-MB-231 cells was
accompanied by an increase in the association between FLAG-LPAi and Rapl, thus
leading to the discovery of a new GPCR interacting protein. These cells primarily express
LPAi endogenously [4]. Studies looking at endogenous LPA receptors could not be
conducted due to lack of effective antibodies against LPA receptors. The binding of
Rapl A to LPAi may thus lead to the establishment of signaling pathways leading to cell
motility. We also observed that LPA stimulates Rapl A to localize to membrane ruffles,
retraction fibers and lamellopodia of motile MDA-MB-231 cells. We have shown that
these cytoskeletal structures are positive for LPA] expression [4], These data strongly
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suggest that RaplA maybe a novel regulator of LPA receptor signaling in breast
carcinoma.
We validated a role for RaplA in LPA-stimulated invasiveness by depleting
endogenous Rapl expression and saw an inhibition of LPA-stimulated breast cancer cell
migration and the formation of invasive stellate structures in 3D invasion cultures. These
3D in vitro tumor invasion models provide important insights into breast cancer biology
including cellular differentiation and tissue organization. Our observations are also
corroborated by Itoh and colleagues who showed that expression of a constitutively
active mutant Rapl construct enhanced invasion of breast cancer cells towards serum
while dominant negative Rapl had the opposite effect [13]. Although the details of the
mechanisms by which Rapl stimulates invasion are unclear, recent findings by Goto et
al. showed that expression of a constitutively active Rapl construct in squamous cell
carcinoma cells resulted in increased stability and nuclear localization of p-catenin which
in turn promoted cell invasion via the transcriptional regulation of genes such as matrix
metalloproteinase-7 (MMP-7) [8]. The involvement of Rapl in the expression of genes
involved in invasiveness in breast cancer has not yet been investigated and will be the
subject of future studies in our laboratory.
We found that Rapl interacts constitutively with IQGAP1 in breast cancer cells using
co-immunoprecipitation assays. We show that depletion of IQGAP1 in MDA-MB-231
cells using shRNA attenuated invasion of cells towards LPA. Previous studies employing
MDA-MB-231 cells have shown that IQGAP1 was enriched at invadopodia, which are
membrane protrusions containing proteolytic enzymes such as membrane-type 1 MMP
that form at contact sites between invasive tumor cells and the extracellular matrix.
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Moreover, depletion of endogenous IQGAP1 by siRNA in these cells significantly
inhibited matrix degradation [29]. In addition, overexpression of the N-terminus of
IQGAP1 in these cells significantly blocked migration of cells towards both LPA and
10% serum and cell invasion towards 10% serum. However, no effect was seen on the
invasion of cells towards LPA. This may be due to other signaling pathways
compensating for the dominant negative effect of the IQGAP1 N-terminus on LPAmediated invasion of cancer cells.
Although P-arrestins are known to regulate cell motility, the downstream pathways by
which they do so are unknown. Our studies identified a novel interaction between Rap 1
and p-arrestin2 and between IQGAP1 and p-arrestin2. We postulate that P-arrestins
regulate the cell cytoskeletal rearrangement by interacting with IQGAP1. Current studies
are underway to further identify the domain of p-arrestin2 responsible for binding
IQGAP1 and to determine if this domain will act as a dominant negative regulator of
breast cancer cell migration and invasion.
We have previously shown that depletion of endogenous P-arrestins blocks breast
cancer migration and invasion. A recent study reported that P-arrestin2 scaffolding of the
RAF-MEK-ERK1/2 signaling components is required for the expression and secretion of
MMP-1 by bronchial epithelial cells in response to diesel exhaust particles (DEPs). Thus,
both IQGAP1 and p-arrestins act to scaffold components of the MEK/ERK pathways that
modulate the cytoskeleton [30], suggesting that IQGAP1 and p-arrestin2 may utilize the
mitogen-activated protein kinase signaling cascade to mediate Rap 1-regulated breast
cancer invasiveness.
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To summarize, our data reveal a novel role for Rapi in the regulation of LPAstimulated breast cancer migration and invasion. We further provide evidence to
implicate the scaffolding proteins IQGAP1 and p-arrestin2 in mediating this process. A
clearer understanding of the molecular pathways underlying breast cancer invasiveness is
expected to aid in the identification of new targets for the design of therapeutics against
metastatic breast cancer.
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3.1. General Discussion and Conclusions
The metastasis of breast cancer, the most common cancer in Canadian women, is the
major cause of breast-cancer related deaths [1], The lipid molecule LPA has previously
been shown to promote breast cancer metastasis in a xenograft mouse model by acting
via its GPCR, LPAi [2, 3]. Work from our laboratory has recently shown that LPA
stimulates the migration and invasion of breast cancer cells, processes required for
metastasis, by acting via the the adapter protein P-arrestin that signals via Ral GTPases to
regulate breast cancer cell migration and invasion [4], In the current study, we propose a
novel mechanism by which LPA regulates the migration and invasion of breast cancer
cells by acting via another small G protein, Rapl.
Our results demonstrate that Rapl A mRNA expression is elevated in samples from
breast cancer patients at stages I-IV of the disease compared to expression in stage 0
samples. According to the American Joint Committee on Cancer, unlike cancer at stage
0, stage I tumor display a locally invasive phenotype [5]. The fact that higher levels of
Rapl A mRNA expression are observed at stage I, compared to stage 0 suggests that
Rapl A may play a role in the acquisition of the invasive phenotype during cancer
progression and other aspects of tumorigenesis or metastasis associated with the
advanced stages. We also found higher levels of Rapl protein expression in the more
invasive breast cancer cells (MDA-MB-231 and Hs578T) compared to the weakly
invasive (MCF-7) and non-tumorigenic (MCF-10A) cells.
Since it can be difficult to interpret changes in expression patterns of proteins
between cells lines, we looked at Rapl protein expression in cells from the MCF-10A
series of isogenic cells [6]. Interestingly, our data shows that MCF-10A DCIS cells

96

expressed the highest levels of Rapl compared to the parental MCF-10A and the
aggressive MCF-10A Met cells. Taken together, these results indicate that Rapl may be
involved in breast cancer.
We show that LPA induces Rapl activity in MDA-MB-231 breast cancer cells, but
not in the non-malignant MCF-10A cells. Stable expression of Rapl A in MCF-10A cells
led to the migration of these cells towards serum, but not LPA, suggesting that other
factors in serum act via a Rapl-mediated pathway to stimulate cancer cell invasion.
Additionally, MCF-10A cells express LPAi at lower levels in comparison to the invasive
breast cancer cells (MDA-MB-231 and Hs578T) [4] and this could explain the lack of
migration in response to LPA.
Knockdown of Rapl expression in breast cancer cells using two separate shRNA
constructs blocked LPA-stimulated migration and invasion of MDA-MB-231 cells. These
results are consistent with previous findings that showed that expression of a
constitutively active Rapl A mutant enhanced breast cancer invasion towards serum,
supporting our studies that Rapl regulates these processes [7]. We sought to determine
whether Rapl regulated the migration and invasion in another breast cancer cell line, the
Hs578T cells. These cells are less invasive than the MDA-MB-231 cells, and express
lower levels of P-arrestin2 [4], However, LPA failed to stimulate Rapl activity in these
cells (data not shown). Thus, we are currently investigating a role for Rapl in LPAstimulated cancer cell migration and invasion using the MDA-MB-435 cells, that we
have previously shown express LPAi and p-arrestin2 [4].
The ability of LPA to stimulate Rapl activity in MDA-MB-231 cells was abrogated
upon knockdown of the adapter protein p-arrestin2. Rapl interacts with the P-arrestin2
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according to our co-immunoprecipitation assays. Thus, (3-arrestin2 appears to form a
complex with Rapl and regulate its activity in response to LPA. These results are in line
with recent findings by Molteni et al. that showed that siRNA-mediated suppression of parrestin2 expression in RBL-2H3 leukemia cells blocked activation of Rapl in response
to keratinocyte-derived chemokine [8].
We also report here that the scaffolding protein IQGAP1 associates with YFP-tagged
Rapl A and endogenous p-arrestin2 in breast cancer cells. Similar localization of
endogenous IQGAP1 and YFP-tagged Rapl A were also observed in MDA-MB-231
cells. Similar to our observations, co-localization of Rapl with IQGAP1 has been
reported in the perinuclear region of activated natural killer cells [9], However, the
isoform of Rapl investigated in this study was Rap lb, since Rap lb is the major isoform
expressed in these cells.
The association of IQGAP1 and p-arrestin2 represents only the second case of
interactions between two scaffolding proteins, to our knowledge. In rat brain extracts, the
scaffolding protein homer has been shown to interact with PDZ-containing proteins
including proline-rich synapse-associate protein and can also dimerize with other homer
molecules [10]. Both IQGAP1 and p-arrestin2 have been reported to facilitate the
scaffolding of the MAPK signaling components [11], suggesting that the association of
P-arrestin2 and IQGAP1 may bring together individual signaling complexes within the
same area of the cell to allow for the spatial regulation of multiple processes including
cell migration.
MDA-MB-231 cells were previously reported to express the highest amount of
IQGAP1 of the breast cancer cells tested [12], Our results show that depleting the
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IQGAP1 levels in these cells abrogated invasion of cells towards LPA, indicating that
IQGAP1 plays a key role in LPA-stimulated invasion of breast cancer cells.
Overexpression of the N-terminus had a dominant negative effect on MDA-MB-231 cell
migration towards LPA and serum. However, this construct failed to exert an effect on
the invasiveness of these cells towards LPA, suggesting that other molecular pathways
may compensate the inhibitory effect of the IQGAP1 N-terminus on cell invasion.
To summarize, our data reveal a novel role for P-arrestin2/IQGAPl/Rapl signaling in
the regulation of LPA-stimulated breast cancer migration and invasion. Our future studies
will investigate the role Rapl plays in regulating breast cancer metastasis in vivo and to
further characterize the interactions between Rapl and P-arrestins, and IQGAP1. A better
understanding of the mechanisms by which LPA regulates breast cancer metastasis will
allow for the development of more effective therapeutics for the treatment of cancer
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